JP2024539946A - プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法 - Google Patents

プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法 Download PDF

Info

Publication number
JP2024539946A
JP2024539946A JP2024524568A JP2024524568A JP2024539946A JP 2024539946 A JP2024539946 A JP 2024539946A JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024539946 A JP2024539946 A JP 2024539946A
Authority
JP
Japan
Prior art keywords
alkyl
pharma
stereoisomer
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539946A5 (cg-RX-API-DMAC7.html
Inventor
ディン,シャオ
チン,リーナ
レン,フェン
シュー,ジェンユー
Original Assignee
インシリコ メディシン アイピー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インシリコ メディシン アイピー リミテッド filed Critical インシリコ メディシン アイピー リミテッド
Publication of JP2024539946A publication Critical patent/JP2024539946A/ja
Publication of JP2024539946A5 publication Critical patent/JP2024539946A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2024524568A 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法 Pending JP2024539946A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/127023 2021-10-28
CN2021127023 2021-10-28
CN2022112270 2022-08-12
CNPCT/CN2022/112270 2022-08-12
PCT/CN2022/128293 WO2023072257A1 (en) 2021-10-28 2022-10-28 Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024539946A true JP2024539946A (ja) 2024-10-31
JP2024539946A5 JP2024539946A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=86159087

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024524568A Pending JP2024539946A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法
JP2024524567A Pending JP2024541910A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024524567A Pending JP2024541910A (ja) 2021-10-28 2022-10-28 プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法

Country Status (11)

Country Link
US (6) US20260015349A1 (cg-RX-API-DMAC7.html)
EP (2) EP4422623A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024539946A (cg-RX-API-DMAC7.html)
KR (2) KR20240095274A (cg-RX-API-DMAC7.html)
CN (2) CN118591533A (cg-RX-API-DMAC7.html)
AR (3) AR127488A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022378858A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235718A1 (cg-RX-API-DMAC7.html)
IL (1) IL312220A (cg-RX-API-DMAC7.html)
TW (3) TW202332677A (cg-RX-API-DMAC7.html)
WO (3) WO2023072240A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
GB202301059D0 (en) 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors
JP2026516849A (ja) * 2023-04-28 2026-05-26 インシリコ メディスン アイピー リミテッド プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤、その組合せ及び使用
WO2024222881A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
CN121057737A (zh) * 2023-04-28 2025-12-02 英矽智能科技知识产权有限公司 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂结晶及其用途
CN117603230B (zh) * 2023-12-15 2025-03-21 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的三并环类化合物
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物
CN117756822B (zh) * 2023-12-20 2025-04-18 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶氨基类化合物
CN117736227B (zh) * 2023-12-20 2025-01-21 英矽智能科技(上海)有限公司 抑制jak和phd的一类化合物
CN117924326B (zh) * 2024-01-23 2025-01-21 英矽智能科技(上海)有限公司 一类抑制jak和phd的三并环类化合物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
JP2008533082A (ja) * 2005-03-18 2008-08-21 グラクソ グループ リミテッド Pde4阻害剤としての1,7−ナフチリジン
JP2011507894A (ja) * 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
JP2011515402A (ja) * 2008-03-18 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 置換4−ヒドロキシピリジン−5−カルボキサミド
JP2016515582A (ja) * 2013-03-29 2016-05-30 武田薬品工業株式会社 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018510200A (ja) * 2015-03-27 2018-04-12 瀋陽三生製薬有限責任公司Shenyang Sunshine Pharmaceutical Co., Ltd. アリール又はヘテロアリール置換の5−ヒドロキシ−1,7−ナフチリジン化合物、その製造方法及び医薬用途
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019060850A1 (en) * 2017-09-25 2019-03-28 Takeda Pharmaceutical Company Limited CYANO-SUBSTITUTED N- (BENZYL OR PYRIDINYLMETHYL) DERIVATIVES-3-HYDROXYPICOLINAMIDE USEFUL AS INHIBITORS OF HIF PROLYL HYDROXYLASE
JP2020535194A (ja) * 2017-09-28 2020-12-03 南京薬捷安康生物科技有限公司 Pde9阻害剤及びその用途
WO2021163344A1 (en) * 2020-02-12 2021-08-19 Amgen Inc. Novel prmt5 inhibitors
WO2021198709A1 (en) * 2020-04-03 2021-10-07 Kinsensus Limited Naphthyridine compounds as inhibitors of mer tyrosine kinase and axl tyrosine kinase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US20110028507A1 (en) * 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2011106226A2 (en) 2010-02-23 2011-09-01 Cornell University Prolylhydroxylase inhibitors and methods of use
WO2013134660A1 (en) * 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146490B (zh) 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN108341777A (zh) 2017-01-23 2018-07-31 四川科伦博泰生物医药股份有限公司 异喹啉酮类化合物及其应用
CN110878096A (zh) 2018-09-05 2020-03-13 石药集团中奇制药技术(石家庄)有限公司 一种1,7-萘啶类衍生物及其制备方法和用途
CN112979541B (zh) 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
JP2008533082A (ja) * 2005-03-18 2008-08-21 グラクソ グループ リミテッド Pde4阻害剤としての1,7−ナフチリジン
JP2011507894A (ja) * 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
JP2011515402A (ja) * 2008-03-18 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 置換4−ヒドロキシピリジン−5−カルボキサミド
JP2016515582A (ja) * 2013-03-29 2016-05-30 武田薬品工業株式会社 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018510200A (ja) * 2015-03-27 2018-04-12 瀋陽三生製薬有限責任公司Shenyang Sunshine Pharmaceutical Co., Ltd. アリール又はヘテロアリール置換の5−ヒドロキシ−1,7−ナフチリジン化合物、その製造方法及び医薬用途
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019060850A1 (en) * 2017-09-25 2019-03-28 Takeda Pharmaceutical Company Limited CYANO-SUBSTITUTED N- (BENZYL OR PYRIDINYLMETHYL) DERIVATIVES-3-HYDROXYPICOLINAMIDE USEFUL AS INHIBITORS OF HIF PROLYL HYDROXYLASE
JP2020535194A (ja) * 2017-09-28 2020-12-03 南京薬捷安康生物科技有限公司 Pde9阻害剤及びその用途
WO2021163344A1 (en) * 2020-02-12 2021-08-19 Amgen Inc. Novel prmt5 inhibitors
WO2021198709A1 (en) * 2020-04-03 2021-10-07 Kinsensus Limited Naphthyridine compounds as inhibitors of mer tyrosine kinase and axl tyrosine kinase

Also Published As

Publication number Publication date
JP2024541910A (ja) 2024-11-13
CN118591533A (zh) 2024-09-03
EP4422623A4 (en) 2025-10-29
US12209101B2 (en) 2025-01-28
CA3235718A1 (en) 2023-05-04
US20260015349A1 (en) 2026-01-15
US20250034132A1 (en) 2025-01-30
EP4423074A4 (en) 2025-09-03
WO2023072246A1 (en) 2023-05-04
TW202334134A (zh) 2023-09-01
KR20240093899A (ko) 2024-06-24
AU2022378858A1 (en) 2024-05-02
CN118488838A (zh) 2024-08-13
AR127500A1 (es) 2024-01-31
TW202332677A (zh) 2023-08-16
KR20240095274A (ko) 2024-06-25
TW202334158A (zh) 2023-09-01
EP4422623A1 (en) 2024-09-04
US11780854B2 (en) 2023-10-10
US20240002406A1 (en) 2024-01-04
US12071443B2 (en) 2024-08-27
US20240067661A1 (en) 2024-02-29
US11731987B2 (en) 2023-08-22
IL312220A (en) 2024-06-01
EP4423074A1 (en) 2024-09-04
AR127501A1 (es) 2024-01-31
WO2023072257A1 (en) 2023-05-04
US20230192723A1 (en) 2023-06-22
WO2023072240A1 (en) 2023-05-04
US20230192688A1 (en) 2023-06-22
AR127488A1 (es) 2024-01-31

Similar Documents

Publication Publication Date Title
US12071443B2 (en) Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof
CN104822658B (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
EP4289835A1 (en) Cdk inhibitor
JP7847123B2 (ja) 化合物、組成物及び方法
TW202430152A (zh) 野生型kit抑制劑
EP3676251A1 (en) N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives useful as hif prolyl hydroxylase inhibitors
US20230219986A1 (en) Novel aminopyrimidine egfr inhibitor
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN113166077A (zh) 抗细菌化合物
JP2025528794A (ja) サイクリン依存性キナーゼ(cdk)12および/またはcdk13の阻害剤、ならびにその使用
TW202010500A (zh) 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物
JP2025529942A (ja) Ep300/cbp調整剤及びその製造方法と使用
HK40114116A (en) Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN116507608A (zh) 化合物、组合物和方法
JP2023542789A (ja) ピラゾール化合物並びにその調製方法及び使用
KR20160040182A (ko) 다중 키나제억제제인 융합된 트리사이클릭 아미드 화합물
EP4701663A1 (en) Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260710